PBM lowers co-pay for CFC-free inhalers

May 7, 2007

UnitedHealth Pharmaceutical Solutions (UHPS) lowered the co-pay for CFC-free brand-name inhalers.

UnitedHealth Pharmaceutical Solutions (UHPS) lowered the co-pay for CFC-free brand-name inhalers. UHPS has moved Xopenex HFA to Tier 1-the lowest co-pay tier-on its prescription drug list so that commercial members have an affordable, effective way to continue managing their asthma without supply issues or added cost. As a result, the co-pay for CFC-free Xopenex ranges from $5 to $10, depending on the member’s co-pay benefit. CFC-containing albuterol inhalers, the industry standard for 25 years, are being phased out because of their harmful effect on the earth’s ozone layer. The new CFC-free brand-name inhalers, according to UHPS, are just as effective but have a higher cost.

 

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.